Tandem

1.1 Identity and operating model

Forbes reports that Sahir Jaggi started Forus in 2023 under the Tandem name to automate the administrative backend of prescriptions. The workflow begins when a physician writes a prescription and addresses prior authorization, prior medication history, pharmacy restrictions, affordability, and real-time status visibility. PYMNTS separately describes Tandem Technology as raising capital for software that eases writing and obtaining prescriptions, with paperwork and phone calls automated for prior authorization and pharmacy routing. The product is therefore best characterized as healthcare operations infrastructure, not a diagnostic system. Its identity is complicated by the July 2026 DataMatrix review, which says Tandem AI rebranded as Forus after a $160 million funding round; the underlying medication prior-authorization product is described as the same platform.[CO001, CO002, CO003, CO004]

1.2 Financing, monetization, and scale

The financing record is directionally strong but not internally uniform. Forbes reports a $1 billion valuation, $160 million in total funding, and annualized revenue above $50 million after revenue had roughly quintupled during the year. PYMNTS, citing unnamed sources, reports a $100 million round led by Accel at a $1 billion valuation and $137 million raised to date. These figures should not be blended: the two reports may reflect different financing cutoffs or definitions, and neither establishes cash available, burn, runway, margin, or a GAAP revenue base. Forbes says providers and patients are not charged and that pharmaceutical companies are commercial counterparties, while the company reportedly expects millions of patients to use its services in 2026. Public evidence does not establish active customer count or headcount.[CO005, CO006, CO007, CO008, CO009]

1.3 Leadership and stakeholder map

The strongest public leadership evidence is concentrated in Jaggi. Forbes identifies him as founder and says he previously led product at Oscar Health, giving him direct exposure to prescription-coverage friction. A separate OpenEvidence release quotes Adam Harris, MD, as Tandem's Head of Clinical Intelligence, while the Doctor Care Anywhere announcement quotes Lukas Saari as CEO and co-founder of Tandem Health in the European clinical-workflow business. Those references may reflect operating entities or a broader leadership team, but they do not disclose board composition, investor control rights, or succession coverage. Partnerships with OpenEvidence and Doctor Care Anywhere demonstrate external workflow integration; they do not independently verify customer retention or economics. The stakeholder table therefore separates capital providers, operating partners, and governance diligence asks.[CO003, CO010, CO011]

1.4 Milestones and diligence implications

Tandem's trajectory combines a 2023 founding, a 2025 founder recognition, 2026 financing and valuation disclosures, and two 2026 workflow partnerships. The external context is material: Holland & Knight's 2026 survey of state laws describes requirements for clinical circumstances, human review, disclosures, and monitoring when AI is used around prior authorization, while Stanford researchers warn that opaque insurance AI can amplify wrongful denials without meaningful human review. These are sector-level constraints rather than allegations of a Tandem violation. DataMatrix, a competitor, argues Tandem is strongest for medication authorization automation but does not publish denial or accuracy metrics for Tandem. The company has not publicly supplied enough evidence to establish board oversight, customer concentration, security controls, realized revenue quality, or whether the reported funding totals are comparable.[CO012, CO013, CO014]

1.5 Exhibits

2.1 Market boundary and status-quo substitutes

The defensible core market is medication-access workflow automation after a clinician writes a prescription: insurance checks, documentation assembly, prior-authorization submission and appeal, affordability support, and pharmacy or site-of-care routing. The boundary excludes the value of the medicine itself, insurer premium revenue, general clinical decision support, and prior authorizations for procedures, imaging, and durable medical equipment. Current substitutes are practice staff, payer portals, fax, telephone follow-up, and outsourced authorization specialists. Tandem is reported to be free to providers and patients, but the retained sources do not disclose the paying customer or pricing basis. That missing commercial boundary matters more to sizing than the company's reported valuation.[CM001, CM002, CM015, CM016]

2.2 Evidence-constrained sizing

No assigned source publishes a company-specific TAM, SAM, or SOM, so the market must be triangulated without converting unrelated denominators into software revenue. ASHP reported $915 billion of US prescription-drug spending in 2025 and projected more than $1 trillion in 2026; CMS separately reported more than $100 billion of gross Medicaid prescription-drug spending in 2024. Those figures describe drug economics, not Tandem's addressable fees. A closer operational lens is CAQH's $18.7 billion estimate of potential medical administrative savings from further automation, while 40% electronic prior-authorization penetration indicates remaining process headroom. Neither figure identifies eligible medication transactions, willingness to pay, or Tandem's attainable share.[CM003, CM004, CM005, CM006, CM008, CM009]

2.3 Buyer, user, payer, and adoption path

Providers and access teams are the operational users, patients are the beneficiaries, and insurers or pharmacy-benefit managers control coverage decisions. Public evidence does not identify which participant funds Tandem, so buyer segmentation remains provisional: a practice or health system can justify adoption through lower labor and faster therapy starts, while a biopharma sponsor could value fewer abandoned prescriptions. The adoption path begins with EHR integration and reliable handling of routine cases, then depends on appeals, payer-specific exceptions, staff escalation, and patient participation. The strongest demand signal is workflow pain: the AMA reported 39 prior authorizations per physician per week, widespread care delays, treatment abandonment, and dedicated authorization staffing.[CM010, CM011, CM012, CM013, CM014, CM015]

2.4 Drivers, constraints, and underwriting gaps

Growth is supported by rising prescription use, high specialty-drug spending, and a large gap between electronic and manual authorization workflows. Regulation can reduce friction but remains uneven: CMS's optional GENEROUS Medicaid model would introduce uniform coverage criteria only for participating states and manufacturers. Execution risk is material because payer rules vary, integrations can constrain deployment, and edge cases still require judgment and communication. DataMatrix, a competitor rather than an independent benchmark, argues that Tandem is best suited to simpler medication authorizations and that broader categories need human support. Underwriting therefore requires transaction eligibility, exception rates, authorization outcomes, implementation costs, contracted pricing, retention, and independently verified customer ROI.[CM004, CM007, CM009, CM016]

2.5 Exhibits

3.1 Competitive landscape and buyer jobs

Tandem's relevant market is broader than electronic prior-authorization form completion. Its public workflow spans prescription intake, benefits and clinical-document collection, prior authorization submission, appeals, patient-support enrollment, pharmacy routing, and status communication. Rx Almanac describes Forus, the company's later name, as free to providers and patients and paid through biopharma partnerships, while the company's own practice page says it is free and supports multiple plans, drugs, and pharmacies. That creates a three-sided competitive set: medication-access vendors selling to manufacturers, provider workflow tools, and infrastructure platforms that already sit between prescribers, pharmacies, payers, or revenue-cycle teams. The buyer must therefore compare not just automation depth but the network position and data rights needed to complete a case after an initial submission.[CP001, CP002, CP004]

3.2 Capability, distribution, and trust comparison

The capability comparison is asymmetric by design. CoverMyMeds and Surescripts emphasize network reach or rapid decisions for qualifying, programmable cases; Waystar embeds authorization in a broader revenue-cycle suite; Cohere operates primarily on the payer side; and DataMatrix represents the human, end-to-end outsourcing substitute. Tandem/Forus instead claims a medication-access workflow that combines authorization, appeals, affordability, and pharmacy routing. Independent comparison material places Tandem among deeper specialty- medication options but also says its coverage is primarily medication prior authorizations, while the competitor's own critique says automation can leave gaps when cases require payer nuance, phone calls, or human judgment. These are positioning statements rather than controlled benchmark results, so the matrix marks unsupported performance and compliance cells as unknown rather than treating vendor claims as proof.[CP005, CP006, CP007, CP008, CP009, CP010]

3.3 Pricing, packaging, and switching

Public pricing is not comparable on a clean per-case basis. Tandem advertises no charge to providers and patients, while the independent profile says the paying-side motion is biopharma partnerships and that contract economics are undisclosed. DataMatrix advertises flexible hourly pricing starting at $12 per hour, but it is a human-services competitor with a different cost and accountability model. Incumbent platforms do not publish a comparable Tandem-style list price in the assigned evidence. Switching costs are consequently likely to concentrate in workflow integration, payer and pharmacy connectivity, clinical-document quality, and the accumulated operational knowledge of exception paths, not merely software license price. A diligence process should test migration effort, exportability of case history, multi-homing across e-PA portals, and whether manufacturer reporting creates lock-in.[CP012, CP014]

3.4 Moat durability and displacement risk

Tandem's moat case rests on combining workflow placement with a data and distribution network: the product page says it can operate through an EHR or uploaded records, while partner reporting describes integration into a clinical environment. That can reduce office burden, but the same evidence shows powerful alternatives. Optum describes electronic authorization as a real-time exchange with multiple portals and plan-specific review; Waystar claims a broad provider footprint and revenue-cycle suite; and Surescripts' touchless model can be dramatically faster when payer participation and programmable criteria are present. The adverse operating lesson from the Change Healthcare cyberattack is that healthcare connectivity is a concentration and resilience risk: AMA survey respondents reported ongoing disruption to eligibility, claims, remittance, and payments. Tandem's differentiation may persist in complex medication access, but durability depends on proving exception performance, redundancy, security controls, and manufacturer value that infrastructure incumbents cannot easily replicate.[CP015, CP016, CP017, CP018, CP019]

3.5 Exhibits

4.1 Revenue model is plausible but internally inconsistent

The clearest public description is a subsidized workflow model: providers and patients use Tandem without charge, while partnerships and enterprise contracts are reported as the monetization layer. The OpenEvidence partnership shows how Tandem can enter the clinical workflow at the prescribing decision and carry the process through prior authorization, affordability support, and pharmacy routing, but the announcement contains no commercial terms. A Preqin profile creates an important contradiction by asserting that practices pay through subscriptions. Until management reconciles whether provider access is universally free, selectively subsidized, or sold under some contracts, neither payer identity nor revenue quality can be underwritten. Public list price of zero for users is therefore a distribution fact, not evidence of revenue, margin, or willingness to pay among enterprise partners.[CI001, CI002, CI003, CI004]

4.2 Activity signals do not resolve unit economics

PYMNTS reported that Tandem expected millions of patients to use its service during 2026, which suggests potential transaction volume but does not state active patients, completed authorizations, recognized revenue, or retention. A competitor assessment argues that Tandem is concentrated in medication prior authorizations and does not publish denial or accuracy rates; because that assessment is issued by DataMatrix, it is adverse competitive evidence rather than an independent benchmark. Linear Health's claimed automation range of $2 to $5 per authorization and outsourcing range of $7 to $15 are useful only as vendor-authored market reference points. They cannot be substituted for Tandem pricing, CAC, payback, contribution margin, implementation cost, appeal labor, or partner revenue share. Those company-specific inputs remain absent from the assigned evidence.[CI008, CI009, CI010, CI011]

4.3 Financing extends capacity but does not establish runway

Secondary sources reported a roughly $100 million 2026 financing at a $1 billion valuation, while PYMNTS reported $137 million raised to date on January 26, 2026. Preqin says the February financing was intended for hiring, product development, and deeper partnerships. None of those figures states cash on hand, debt, restricted cash, monthly burn, working-capital requirements, or remaining runway; capital raised must not be treated as capital still available. External demand may be durable: Mercer projects specialty drugs to exceed half of drug spending in 2026-2027 and beyond, and Cardinal Health reports active reassessment of hub-vendor models among 200 biopharma manufacturers. Yet that backdrop can increase both opportunity and integration, compliance, and service-delivery costs.[CI005, CI006, CI007, CI014, CI015]

4.4 Financial verdict and underwriting threshold

The investable thesis is a high-volume prescription-access network whose provider adoption is accelerated by a zero user price and whose economics are captured from enterprises elsewhere in the drug supply chain. The evidence does not yet show that this activity converts into recognized revenue or gross profit, and the conflicting subscription description weakens confidence in payer and contract architecture. Policy risk also matters: the National Health Law Program reports that some plans already use AI to support denials and that several states require human oversight for adverse determinations. Those constraints may protect patients while preserving costly exception handling. Underwriting should therefore remain conditional on contract-level revenue evidence, cohort retention, gross-margin bridges, customer concentration, cash and burn, and a management reconciliation of the provider-pricing conflict.[CI003, CI012, CI013, CI016]

4.5 Exhibits

5.1 Product scope and customer workflow

Tandem is positioned as a workflow product for the administrative work that begins when a clinician writes a prescription. The disclosed sequence covers intake, prior-authorization paperwork, appeals, affordability support, and routing to a pharmacy or site of care. Forbes adds useful operating detail: the system is reported to collect prior-medication context and pharmacy restrictions, while doctors and patients can follow status in real time. This is a broader workflow proposition than a point form-filler, but the evidence remains largely company-originated or based on management descriptions. No reviewed source establishes coverage across every drug class, payer, EHR, or exception path, so the product should be underwritten as medication-access automation with unresolved edge-case boundaries.[CE001, CE002, CE003, CE004, CE005]

5.2 Workflow, integrations, and operating architecture

The clearest external integration proof is the announced OpenEvidence connection, which links clinical decision support to prescription generation and prior-authorization submission. Tandem's described execution layer then handles appeals, affordability, and destination routing. The architecture map below is therefore a functional evidence map, not a claim about Tandem's private software stack. Adjacent vendors show what enterprise interoperability can require: Humata markets proprietary APIs plus HL7/FHIR, while Waystar publicly lists REST, web services, sFTP, HL7, batch, X12 EDI, and robotic-process interfaces. Tandem's assigned evidence does not disclose equivalent protocols, data models, hosting, model vendors, fallback operations, or integration certification, leaving implementation effort and scalability unquantified.[CE007, CE008, CE010, CE011, CE012, CE016]

5.3 Maturity, differentiation, and operational dependencies

Product maturity is supported by reported production use and a commercial model tied to pharmaceutical-company relationships, not by a published release history or technical benchmark. The potential differentiation is orchestration across provider, patient, payer, affordability, and pharmacy steps, plus real-time status visibility. That breadth also creates dependencies on accurate clinical data, payer rules, patient responsiveness, supported EHRs, and pharmacy inventory. A competitor review argues that Tandem is strongest for relatively straightforward medication authorizations and may require supported EHR integrations; its commercial bias warrants caution, but the critique identifies concrete exception-handling and human-oversight questions that should be tested in references and workflow logs.[CE004, CE005, CE006, CE009, CE010]

5.4 Trust, safety, compliance, and quality controls

The reviewed pool does not document Tandem-specific security certifications, business associate terms, audit logs, model evaluation, bias testing, human-review thresholds, uptime, incident history, or disaster recovery. These are material omissions for software processing prescription and insurance data. KFF identifies inaccurate or biased outcomes and privacy breaches as sector risks, and notes that some coverage decisions require individualized clinical review rather than algorithm-only adjudication. Optum's disclosed governance board and human-in-the-middle approach provide a useful diligence benchmark, not evidence that Tandem uses the same controls. Investment diligence should require control artifacts and measured exception outcomes before treating the workflow breadth as safe or reliable at scale.[CE013, CE014, CE015, CE016]

5.5 Exhibits

6.1 Customer base and economic roles

The available evidence points to a multi-sided network rather than a conventional single-buyer software account. Provider practices and health systems are the principal workflow users, patients are beneficiaries who reportedly pay nothing, and biopharma companies appear to be the commercial customer segment most clearly described in the retained material. Pulse 2 relayed Forus's statements that thousands of practices and health systems use the platform across all 50 states and that five of the ten largest global biopharma companies work with it. PYMNTS separately reported that the service is free to providers and patients. Those statements support segmentation, but they do not disclose contracts, revenue mix, procurement owners, or whether every counted practice is active and paying through another side of the network. OpenEvidence is best classified as a distribution and workflow partner, not automatically as a customer.[CU001, CU005, CU007, CU008, CU014]

6.2 Adoption trajectory is broad but largely self-reported

Current third-party articles relay strong company-supplied adoption indicators: provider adoption reportedly increased tenfold year over year in each of the prior two years; usage spans thousands of practices and health systems; and the service reportedly reaches patients in nearly 80% of U.S. residential ZIP codes. PYMNTS also reported management's expectation that millions of patients would use the service in 2026. These measures are directionally consistent with expansion, but they mix growth, installed footprint, geographic reach, and a forward-looking patient forecast. They therefore cannot be combined into a conversion funnel or treated as equivalent active usage. No retained source supplies a dated active-account series, repeat-use rate, paid deployment count, or denominator for the tenfold growth statement. The trajectory is promising, but not independently audited.[CU004, CU005, CU006, CU009]

6.3 Named proof, retention, and concentration remain thin

The OpenEvidence partnership is the clearest named relationship in the assigned evidence. It connects clinical decision support to prescription generation and prior authorization submission, but the announcement does not disclose deployment volume, customer conversion, treatment-start improvement, or commercial terms. Aggregate references to thousands of provider organizations and five leading biopharma companies do not identify accounts or distinguish pilots from scaled production. None of the retained Tandem or Forus sources reports NRR, GRR, churn, renewal, contract length, or customer concentration. Consequently, retention and top-customer exposure remain private-evidence questions rather than negative conclusions. A similarly named European clinical-documentation company, Tandem Health, reports a different integration footprint; those figures must not be attributed to this prescription-access business.[CU001, CU005, CU007, CU015, CU016]

6.4 Workflow value depends on exception handling and production execution

The proposed customer journey is coherent: a clinical decision can trigger a prescription, authorization and appeal work, affordability support, pharmacy routing, and ultimately treatment initiation. Yet the retained evidence does not quantify how often Tandem completes that sequence or where cases drop out. A competitor assessment says the product is attractive for simple medication authorizations while arguing that complex cases still require human judgment and follow-up; because the publisher sells an alternative service, that critique is adverse evidence, not an independent benchmark. Separate named deployments from Alithya and MCG show what diligence-grade proof can look like: throughput measures, production status, named counterparties, implementation detail, and explicit baselines. Those comparator outcomes do not establish Tandem's performance, but they define the evidence needed to underwrite durable customer value.[CU003, CU010, CU011, CU012, CU013]

6.5 Exhibits

7.1 Regulatory and legal exposure

Tandem operates in a workflow where protected health information, payer decisions, and medication access can intersect. The assigned evidence does not establish that Tandem makes clinical or coverage decisions, but the joint OpenEvidence release says the partnership connects clinical decision-making with prescription generation and prior authorization submission. That boundary needs to be explicit in product design and contracts. Foley says an AI vendor processing PHI needs a business associate agreement defining permitted data use and safeguards, while ITECS says a BAA alone does not make an unsafe workflow compliant. Manatt reports that multiple states now prohibit payers from using AI alone for adverse coverage decisions and that some healthcare-AI laws add notice, consent, or professional-review duties. These sources establish the regulatory direction, not Tandem's compliance. Residual exposure therefore remains high until diligence verifies data flows, minimum-necessary access, retention, subprocessors, human accountability, audit records, and state-by-state workflow classification.[CR005, CR006, CR007, CR008, CR009]

7.2 Operational, quality, and dependency exposure

Tandem's described product spans paperwork, phone calls, prior authorizations, appeals, affordability support, and pharmacy routing. This creates a chain of external handoffs where a payer-rule change, integration outage, queue backlog, routing failure, or incorrect automation can delay medication access even if the core software remains available. OpenEvidence also says it relies on signed content agreements with several medical publishers, adding an upstream content relationship to the partnership chain. Comparable-sector evidence shows the downside can be material: HIPAA Journal reports that the Change Healthcare outage halted critical payment and claims systems for about two months, and Becker's reports widespread care and financial disruption among hospitals. These events did not involve Tandem and do not prove Tandem has suffered an incident; they show why redundancy, recovery objectives, manual fallback, vendor oversight, and tested incident response are investment-critical. No Tandem-specific uptime, recovery, incident-history, fallback, or concentration evidence appears in the assigned pool.[CR001, CR004, CR010, CR011, CR015]

7.3 Financial and execution exposure

PYMNTS reported in January 2026 that Tandem was raising $100 million at a reported $1 billion valuation and had raised $137 million to date. That is financing evidence, not evidence of cash available, recurring revenue, gross margin, burn, runway, or customer concentration. The same article says the service is free to patients and providers, which increases the importance of identifying the actual payer, pricing mechanism, implementation cost, and margin by workflow. A competitor review from DataMatrix characterizes Tandem as suitable for simpler medication authorizations and says its denial rate is not published. Because DataMatrix sells an alternative service, those statements are adverse directional evidence rather than an independent performance benchmark. The sparse company-domain message, "Tandem is nowLearn More," also leaves current public identity and transition details unclear. The underwriting position should remain conditional: failure to produce production quality, resilience, concentration, data-governance, and unit-economics evidence is a thesis-break trigger, not a disclosure inconvenience.[CR002, CR003, CR012, CR013, CR014, CR016]

7.4 Exhibits

8.1 Investment view and price discipline

The investable thesis is that Tandem can convert a large administrative bottleneck into a scalable medication-access network. Publicly reported product descriptions say the platform automates prior authorizations, appeals, enrollment forms, and pharmacy routing, while an OpenEvidence partnership connects clinical decision support to prescription execution. A Doctor Care Anywhere deployment provides a concrete operating signal, with the partner describing use across 60,000 consultations per month. These are strategic and workflow indicators, not proof of revenue quality or gross margin. The anti-thesis is therefore price-sensitive: Tandem is offered at no cost to providers and patients in the cited reporting, while monetization terms, customer concentration, and unit economics remain unclear. A reported $1 billion post-money valuation and a reported $100 million financing should be treated as reported financing context, not independently verified fair value.[CV001, CV002, CV003, CV004, CV005]

8.2 Scenario valuation and downside

Scenario analysis is constrained by missing company financials. The bull case assumes the reported financing closes near the cited valuation, adoption expands through partners, and Tandem develops a durable biopharma or provider monetization layer; this could support a premium outcome, but no precise target return is supportable from the retained evidence. The base case treats the $1 billion mark as an unverified private financing reference and requires evidence of paid deployments, recurring revenue, gross margin, and renewal behavior before accepting it as an underwriting input. The bear case is a repricing if fundraising reports do not translate into paid scale, if the product remains limited to simpler authorization cases, or if workflow and integration complexity forces human services around the software. Public comparable evidence is directional only: Waystar trades at a reported enterprise-value-to-revenue multiple of 5.01x, but it is a profitable public RCM company with a materially different maturity and disclosure profile.[CV006, CV007, CV008, CV009, CV010]

8.3 Entry conditions and thesis-break triggers

A decision should remain conditional until management supplies a financing and operating packet. The minimum diligence set is a current cap table and term sheet, liquidation preference and participation terms, post-money ownership, debt and runway, paid customer count, cohort retention, revenue by customer and partner, gross margin by workflow, and evidence that integrations can scale beyond a narrow medication subset. The market is competitive and segmented: Black Book's 2026 provider survey ranked Infinx first in provider-side prior authorization automation and described prior authorization as a top operational bottleneck for 71% of validated respondents. DataMatrix's competitor review says Tandem is useful for simpler medication authorizations but not a complete end-to-end service; that is a competitor-issued view rather than an independent benchmark, but it identifies a testable product-boundary risk. The thesis breaks on a down round, weak paid conversion, material concentration, or inability to show reliable outcomes and governance.[CV011, CV012, CV013, CV014, CV015]

8.4 Exhibits